Stelliam Investment Management LP Lifted Barrick Gold (Call) (ABX) Position By $450,000; Meridian Bioscience (VIVO) Shorts Down By 0.18%

June 15, 2017 - By Michael Collier

Stelliam Investment Management Lp increased Barrick Gold Corp (Call) (ABX) stake by 1.56% reported in 2016Q4 SEC filing. Stelliam Investment Management Lp acquired 30,000 shares as Barrick Gold Corp (Call) (ABX)’s stock declined 17.45%. The Stelliam Investment Management Lp holds 1.96 million shares with $31.24M value, up from 1.93 million last quarter. Barrick Gold Corp (Call) now has $17.81 billion valuation. The stock declined 1.82% or $0.29 reaching $15.66 on the news. About 5.21 million shares traded. Barrick Gold Corp (USA) (NYSE:ABX) has declined 8.26% since June 15, 2016 and is downtrending. It has underperformed by 24.96% the S&P500.

Meridian Bioscience Incorporated (NASDAQ:VIVO) had a decrease of 0.18% in short interest. VIVO’s SI was 3.67M shares in June as released by FINRA. Its down 0.18% from 3.68M shares previously. With 371,600 avg volume, 10 days are for Meridian Bioscience Incorporated (NASDAQ:VIVO)’s short sellers to cover VIVO’s short positions. The SI to Meridian Bioscience Incorporated’s float is 8.87%. About 42,514 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since June 15, 2016 and is downtrending. It has underperformed by 43.54% the S&P500.

Meridian Bioscience, Inc. is a life science firm engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction /quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. The company has market cap of $636.17 million. The Company’s divisions include Diagnostics and Life Science. It has a 21.33 P/E ratio. The Diagnostics segment includes manufacturing activities in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA.

Since January 26, 2017, it had 2 insider buys, and 0 insider sales for $101,156 activity. The insider BALDINI LAWRENCE bought 4,000 shares worth $50,800. On Thursday, February 2 the insider LUEKE MELISSA bought $50,356.

Investors sentiment increased to 1.27 in 2016 Q4. Its up 0.05, from 1.22 in 2016Q3. It improved, as 14 investors sold Meridian Bioscience, Inc. shares while 48 reduced holdings. 24 funds opened positions while 55 raised stakes. 35.77 million shares or 1.94% less from 36.48 million shares in 2016Q3 were reported. Colorado-based Janus Cap Limited Liability Co has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Moreover, California Public Employees Retirement has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 87,500 shares. Wellington Mgmt Gp Limited Liability Partnership holds 0% or 19,600 shares in its portfolio. Cardinal Cap reported 39,963 shares. Amer Intl Gru has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Susquehanna International Gru Llp accumulated 65,399 shares or 0% of the stock. Johnson Inv Counsel Inc stated it has 25,277 shares. California State Teachers Retirement Sys reported 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Tiaa Cref Inv Mngmt Ltd Liability reported 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Vanguard Grp Inc has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Retail Bank Of Montreal Can has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). North Star Management Corp owns 40,300 shares. Hl Fincl Llc reported 16,178 shares. New York-based Renaissance Tech Ltd Llc has invested 0.05% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Voya Invest Management Ltd Liability Co invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).

Among 3 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Meridian Bioscience had 6 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Buy” rating given on Monday, March 28 by Hilliard Lyons. As per Monday, March 21, the company rating was downgraded by Hilliard Lyons. Canaccord Genuity maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) on Thursday, September 10 with “Hold” rating.

Stelliam Investment Management Lp decreased Arris Intl Inc stake by 355,000 shares to 1.28 million valued at $38.64M in 2016Q4. It also reduced Gamestop Corp New (NYSE:GME) stake by 552,500 shares and now owns 1.37 million shares. Amag Pharmaceuticals Inc (NASDAQ:AMAG) was reduced too.

Among 22 analysts covering Barrick Gold Corp. (NYSE:ABX), 11 have Buy rating, 1 Sell and 10 Hold. Therefore 50% are positive. Barrick Gold Corp. had 56 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, May 3. TD Securities downgraded Barrick Gold Corp (USA) (NYSE:ABX) on Wednesday, December 21 to “Hold” rating. The stock of Barrick Gold Corp (USA) (NYSE:ABX) earned “Buy” rating by BMO Capital Markets on Monday, April 3. Clarkson Capital initiated the shares of ABX in report on Tuesday, February 16 with “Neutral” rating. The stock of Barrick Gold Corp (USA) (NYSE:ABX) earned “Buy” rating by Goldman Sachs on Wednesday, October 5. The stock has “Hold” rating by Mackie on Friday, February 19. The firm earned “Hold” rating on Wednesday, March 23 by Deutsche Bank. The stock has “Buy” rating by RBC Capital Markets on Thursday, May 25. The company was initiated on Wednesday, September 7 by Berenberg. The rating was upgraded by Canaccord Genuity on Friday, July 31 to “Sell”.